In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

The human skin map – which has been published in the journal Nature and is freely available here – is just one facet of the ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Long-term considerations: While short-term forecasting remains a priority, forecasters also keep an eye on medium and ...